{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:20:32Z","timestamp":1788985232382,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002913","name":"Vlaamse Regering","doi-asserted-by":"publisher","award":["HBC.2021.1130"],"award-info":[{"award-number":["HBC.2021.1130"]}],"id":[{"id":"10.13039\/501100002913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007753","name":"It\u00e4-Suomen Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007753","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jconrel.2025.113823","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T12:04:38Z","timestamp":1746533078000},"page":"113823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Novel in vitro model for intravitreal drug dissolution and release studies of small molecules and their long-acting formulations"],"prefix":"10.1016","volume":"383","author":[{"given":"Teemu","family":"Sorsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"del Amo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonna","family":"Laitinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliia","family":"Pilipenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arto","family":"Urtti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Subrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113823_bb0005","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.jconrel.2025.113823_bb0010","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/JEP.S259298","article-title":"Current and future anti-VEGF agents for neovascular age-related macular degeneration","volume":"13","author":"Kaiser","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.113823_bb0015","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.drudis.2019.02.001","article-title":"Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties","volume":"24","author":"Subrizi","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2025.113823_bb0020","series-title":"Pharmacol. Eye","first-page":"19","article-title":"Ocular pharmacokinetics","author":"Maurice","year":"1984"},{"key":"10.1016\/j.jconrel.2025.113823_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpb.2015.01.003","article-title":"Intravitreal clearance and volume of distribution of compounds in rabbits: in silico prediction and pharmacokinetic simulations for drug development","volume":"95","author":"del Amo","year":"2015","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenst. EV"},{"key":"10.1016\/j.jconrel.2025.113823_bb0030","article-title":"Pharmacokinetics of intravitreal macromolecules: scaling between rats and rabbits","volume":"159","author":"Sadeghi","year":"2021","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113823_bb0035","article-title":"Aldehyde oxidase 1 activity and protein expression in human, rabbit, and pig ocular tissues","volume":"191","author":"Hammid","year":"2023","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113823_bb0040","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1021\/acs.molpharmaceut.8b00038","article-title":"Binding of small molecule drugs to porcine vitreous humor","volume":"15","author":"Rimpel\u00e4","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113823_bb0045","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1021\/acs.molpharmaceut.5b00849","article-title":"A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by Ranibizumab in patients with neovascular age-related macular degeneration","volume":"13","author":"Hutton-Smith","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113823_bb0050","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1007\/s11095-012-0721-9","article-title":"Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes","volume":"29","author":"Missel","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113823_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123515","article-title":"Manufacturing dexamethasone intravitreal implants: process control and critical quality attributes","volume":"647","author":"Costello","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113823_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122625","article-title":"Reverse engineering the Ozurdex dexamethasone intravitreal implant","volume":"634","author":"Costello","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113823_bb0070","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/jps.24480","article-title":"The PK-eye: a novel in vitro ocular flow model for use in preclinical drug development","volume":"104","author":"Awwad","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113823_bb0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2017.02.047","article-title":"Sustained release ophthalmic dexamethasone: in vitro in vivo correlations derived from the PK-eye","volume":"522","author":"Awwad","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113823_bb0080","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jps.23808","article-title":"Simulation of drug distribution in the vitreous body after local drug application into intact vitreous body and in Progress of posterior vitreous detachment","volume":"103","author":"Loch","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113823_bb0085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejpb.2020.05.005","article-title":"Preclinical challenges for developing long acting intravitreal medicines","volume":"153","author":"Awwad","year":"2020","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Pharm. Verfahrenst. EV"},{"key":"10.1016\/j.jconrel.2025.113823_bb0090","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s13346-021-01043-z","article-title":"In vitro dissolution testing models of ocular implants for posterior segment drug delivery","volume":"12","author":"Adrianto","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2025.113823_bb0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11095-018-2435-0","article-title":"Extended pharmacokinetic model of the rabbit eye for intravitreal and intracameral injections of macromolecules: quantitative analysis of anterior and posterior elimination pathways","volume":"35","author":"Lamminsalo","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113823_bb0100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11095-020-02946-1","article-title":"Extended pharmacokinetic model of the intravitreal injections of macromolecules in rabbits. part 2: parameter estimation based on concentration dynamics in the vitreous, retina, and aqueous humor","volume":"37","author":"Lamminsalo","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113823_bb0105","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1021\/acs.molpharmaceut.1c00236","article-title":"Mechanistic model for the prediction of small-molecule vitreal clearance combining diffusion-limited and permeability-limited clearance","volume":"18","author":"Rimpel\u00e4","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113823_bb0110","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.xphs.2017.04.061","article-title":"Impact of chemical structure on conjunctival drug permeability: adopting porcine conjunctiva and cassette dosing for construction of in silico model","volume":"106","author":"Ramsay","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113823_bb0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00006982-200605000-00005","article-title":"Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration","volume":"26","author":"Kim","year":"2006","journal-title":"Retina Phila. Pa"},{"key":"10.1016\/j.jconrel.2025.113823_bb0120","first-page":"629","article-title":"Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits","volume":"20","author":"Ye","year":"2014","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2025.113823_bb0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fbioe.2018.00199","article-title":"Rheological properties and age-related changes of the human vitreous humor","volume":"6","author":"Tram","year":"2018","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.113823_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261925","article-title":"Determining vitreous viscosity using fluorescence recovery after photobleaching","volume":"17","author":"Srikantha","year":"2022","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2025.113823_bb0135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archopht.1957.00930050093017","article-title":"Elaboration of bicarbonate ion in intraocular fluids. II. Vitreous humor, normal values, AMA","volume":"57","author":"Green","year":"1957","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113823_bb0140","article-title":"Anatomical and Micro-CT measurement analysis of ocular volume and intraocular volume in adult Bama miniature pigs, New Zealand rabbits, and Sprague-Dawley rats","volume":"19","author":"Wu","year":"2024","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2025.113823_bb0145","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1021\/acs.molpharmaceut.5b00731","article-title":"Characterization of the pH and temperature in the rabbit, pig, and monkey eye: key parameters for the development of long-acting delivery ocular strategies","volume":"13","author":"Lorget","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113823_bb0150","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/jps.2600620416","article-title":"Solubility and dissolution of triamcinolone acetonide","volume":"62","author":"Block","year":"1973","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113823_bb0155","series-title":"ICH M10 on Bioanalytical Method Validation - Scientific Guideline","year":"2023"},{"key":"10.1016\/j.jconrel.2025.113823_bb0160","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2013.01.018","article-title":"Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo","volume":"167","author":"Xu","year":"2013","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.jconrel.2025.113823_bb0165","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acs.molpharmaceut.0c00411","article-title":"Diffusion and protein Corona formation of lipid-based nanoparticles in the vitreous humor: profiling and pharmacokinetic considerations","volume":"18","author":"Tavakoli","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113823_bb0170","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1021\/acs.analchem.7b05032","article-title":"Improving the interpretation of small molecule diffusion coefficients","volume":"90","author":"Evans","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2025.113823_bb0175","first-page":"363","article-title":"Transport of indomethacin in the anterior uvea of the albino rabbit","volume":"24","author":"Mochizuki","year":"1980","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113823_bb0180","first-page":"1","article-title":"Intravitreal triamcinolone","volume":"225","author":"Tao","year":"2011","journal-title":"Ophthalmol. J. Int. Ophtalmol. Int. J. Ophthalmol. Z. Augenheilkd."},{"key":"10.1016\/j.jconrel.2025.113823_bb0185","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00006982-200507000-00002","article-title":"Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes","volume":"25","author":"Chin","year":"2005","journal-title":"Retina Phila. Pa"},{"key":"10.1016\/j.jconrel.2025.113823_bb0190","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/jps.2600721221","article-title":"Stability of triamcinolone acetonide solutions as determined by high-performance liquid chromatography","volume":"72","author":"Gupta","year":"1983","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113823_bb0195","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/02713683.2011.593722","article-title":"Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes","volume":"37","author":"Oliveira","year":"2012","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2025.113823_bb0200","unstructured":"Kenacort-A 40, Suspensie Voor Injectie 40 mg\/ml | Geneesmiddeleninformatiebank | College ter Beoordeling van Geneesmiddelen, (Kenacort-A40, Summary of Product Characteristics in Dutch, Medicines Evaluation Board, The Netherlands) 2024. https:\/\/www.geneesmiddeleninformatiebank.nl\/ords\/f?p=111:3::SEARCH:::P0_DOMAIN,P0_LANG,P3_RVG1:H,EN,05341 (accessed August 21, 2024)."},{"key":"10.1016\/j.jconrel.2025.113823_bb0205","doi-asserted-by":"crossref","first-page":"8056","DOI":"10.1021\/acsomega.0c05558","article-title":"Dissolution kinetics of a BCS class II active pharmaceutical ingredient: diffusion-based model validation and prediction","volume":"6","author":"Gao","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.jconrel.2025.113823_bb0210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2013.04.044","article-title":"Mathematical modeling of drug dissolution","volume":"453","author":"Siepmann","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113823_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2023.109638","article-title":"Quantitative intravitreal pharmacokinetics in mouse as a step towards inter-species translation","volume":"235","author":"Puranen","year":"2023","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2025.113823_bb0220","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/02713683.2022.2119254","article-title":"Vitreous humor: composition, characteristics and implication on intravitreal drug delivery","volume":"48","author":"Mishra","year":"2023","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2025.113823_bb0225","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jbiomech.2008.04.015","article-title":"Rheological properties of the vitreous and the role of hyaluronic acid","volume":"41","author":"Nickerson","year":"2008","journal-title":"J. Biomech."},{"key":"10.1016\/j.jconrel.2025.113823_bb0230","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1208\/s12248-011-9272-y","article-title":"Dissolution testing for generic drugs: an FDA perspective","volume":"13","author":"Anand","year":"2011","journal-title":"AAPS J."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:19:14Z","timestamp":1762269554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925004432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":45,"alternative-id":["S0168365925004432"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113823","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel in vitro model for intravitreal drug dissolution and release studies of small molecules and their long-acting formulations","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113823"}}